GSK plc (LSE/NYSE: GSK), a prominent pharmaceutical company with a market capitalization of $71.29 billion and currently ...

Bilateral versus unilateral cases of chronic rhinosinusitis with nasal polyps have notable clinical and laboratory ...

a new biologic treatment for asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps (CRSwNP). If approved, depemokimab would be the first biologic of its kind to offer a six ...

Concerning CRSwNP, GSK intends to secure approval in ... If approved, depemokimab will be the first ultra-long-acting biologic that requires the administration of only one dose every six months.

EMA accepts for review GSK’s MAA for depemokimab for use in asthma with type 2 inflammation and CRSwNP: London, UK Wednesday, January 29, 2025, 09:00 Hrs [IST] GSK plc announced ...

GSK plc has announced that new drug applications have been accepted for review by the China National Medical Products ...

13 CRSwNP is a chronic condition that affects up to 4% of the ... With an industry-leading respiratory portfolio and pipeline of vaccines, targeted biologics, and inhaled medicines, we are focused on ...

LONDON - GSK plc (LSE/NYSE: LON:GSK) has announced the acceptance of regulatory filings in China and Japan for depemokimab, a new biologic treatment for asthma with type 2 inflammation and chronic ...

About Asthma, CRSwNP and type 2 inflammation ... With an industry-leading respiratory portfolio and pipeline of vaccines, targeted biologics, and inhaled medicines, we are focused on improving ...